RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,554,705 | +41.8% | 504,022 | +2.0% | 0.00% | 0.0% |
| Q2 2023 | $8,149,390 | +221.4% | 494,202 | +247.7% | 0.00% | +100.0% |
| Q1 2023 | $2,535,725 | -36.9% | 142,137 | +2.9% | 0.00% | 0.0% |
| Q4 2022 | $4,021,501 | +43.8% | 138,101 | +21.0% | 0.00% | 0.0% |
| Q3 2022 | $2,796,000 | +505.2% | 114,109 | +2.6% | 0.00% | – |
| Q2 2022 | $462,000 | -90.4% | 111,249 | -73.3% | 0.00% | -100.0% |
| Q1 2022 | $4,803,000 | +12.2% | 416,887 | -2.8% | 0.00% | 0.0% |
| Q4 2021 | $4,282,000 | -22.0% | 429,071 | +2.1% | 0.00% | 0.0% |
| Q3 2021 | $5,491,000 | -36.4% | 420,434 | -4.6% | 0.00% | -50.0% |
| Q2 2021 | $8,629,000 | -6.7% | 440,686 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $9,252,000 | -25.7% | 434,960 | +3.8% | 0.00% | 0.0% |
| Q4 2020 | $12,454,000 | +32.8% | 418,922 | -3.2% | 0.00% | 0.0% |
| Q3 2020 | $9,379,000 | -8.5% | 432,820 | -5.9% | 0.00% | 0.0% |
| Q2 2020 | $10,251,000 | +74.3% | 459,723 | +19.0% | 0.00% | 0.0% |
| Q1 2020 | $5,881,000 | -29.5% | 386,348 | +6.3% | 0.00% | 0.0% |
| Q4 2019 | $8,344,000 | +31.9% | 363,396 | +24.0% | 0.00% | 0.0% |
| Q3 2019 | $6,328,000 | +34.1% | 293,086 | +36.6% | 0.00% | +100.0% |
| Q2 2019 | $4,720,000 | -20.7% | 214,498 | -1.2% | 0.00% | 0.0% |
| Q1 2019 | $5,950,000 | +5.0% | 217,066 | +2.9% | 0.00% | -50.0% |
| Q4 2018 | $5,669,000 | -8.2% | 210,876 | -0.4% | 0.00% | 0.0% |
| Q3 2018 | $6,178,000 | +37.0% | 211,794 | +46.9% | 0.00% | +100.0% |
| Q2 2018 | $4,509,000 | +150.2% | 144,219 | +59.3% | 0.00% | – |
| Q1 2018 | $1,802,000 | -20.7% | 90,548 | +15.8% | 0.00% | -100.0% |
| Q4 2017 | $2,272,000 | – | 78,181 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |